title: Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model.
abstract: OBJECTIVE
  Docetaxel (DOC) is a novel microtubule polymerizing agent, with superior antiproliferative properties as compared to paclitaxel. DOC is therefore a potential therapeutic tool for the prevention of restenosis following angioplasty. However, DOC has systemic toxicity such as leukocytopenia, which occurs in a dose-dependent manner. To minimize such adverse effects, we carried out local delivery of low-dose DOC directly to injured vessel sites.
  
  
  METHODS
  The rabbit iliac artery was denuded, and then DOC (2 mg) or control vehicle was administered locally 20 min, via a local drug delivery catheter.
  
  
  RESULTS
  The levels of DOC in the plasma were within ng/ml range, eliminating hematopoietic side effects. Seven days after the local delivery (DOC: n=4, control: n=4), DOC decreased the number of Ki-67-labeled cells in the intima (DOC: 22 +/-10 vs. control: 66 +/- 18 cells/mm(2), P<0.01), indicating a decreased proliferative activity. At 28 days (DOC: n=8, control: n=8), computer-assisted morphometric analysis demonstrated that DOC significantly reduced the intimal area (DOC: 0.15 +/- 0.13 vs. control: 0.70 +/- 0.13 mm(2), P<0.01). There was also a decrease in medial area in the DOC-treated vessels (DOC: 0.62 +/- 0.17 vs. control: 1.13 +/- 0.38 mm(2), P<0.01).
  
  
  CONCLUSIONS
  Local delivery of DOC, even after a single low-dose administration, effectively inhibits neointimal hyperplasia. Such administration is associated with a minimal likelihood of systemic adverse effects (leukocytopenia), but potentially induces local toxicity (a decrease in medial wall thickness) due to extensive cytotoxic effect.
authors.affiliation: National Cardiovascular Center, Division of Cardiology, Department of Medicine, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. syasuda@hsp.ncvc.go.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yasuda
authors.forename: Teruo
authors.initials: T
authors.lastname: Noguchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Gohda
authors.forename: Takashi
authors.initials: T
authors.lastname: Arai
authors.forename: Nobumasa
authors.initials: N
authors.lastname: Tsutsui
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Takehisa
authors.initials: T
authors.lastname: Matsuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nonogi
mesh_terms: D000287:Administration, Topical; D000704:Analysis of Variance; D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000494:pharmacology*; D002404:Catheterization / Q000009:adverse effects*; D000077143:Docetaxel; D016503:Drug Delivery Systems; D006965:Hyperplasia; D007083:Iliac Artery / Q000473:pathology; D007091:Image Processing, Computer-Assisted; D007958:Leukocyte Count; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology*; D011817:Rabbits; D043823:Taxoids; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel